Holen Sie sich die Stockscreener-App
21.80
0.51%
0.11
Handel nachbörslich:
21.20
-0.60
-2.75%
Schlusskurs vom Vortag:
$21.69
Offen:
$21.61
24-Stunden-Volumen:
834.79K
Relative Volume:
0.61
Marktkapitalisierung:
$13.99B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
14.53
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+3.07%
1M Leistung:
+3.02%
6M Leistung:
+3.96%
1J Leistung:
-21.58%
1-Tages-Spanne:
$21.59
$21.86
1-Wochen-Bereich:
$21.41
$22.30
52-Wochen-Spanne:
$17.23
$28.56
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
21.80 | 13.01B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Yahoo Finance
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize
Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World
Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - GlobeNewswire Inc.
Why Genmab Stock Smashed It On Monday - Barchart.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX
Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX
Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX
Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com
Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com
Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com
GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance
Genmab ADR (NASDAQ: GMAB) Jumps 1.19% In Recent Session. Here’s Everything You Need To Know. - Stocksregister
AGCO Corp (AGCO) Beta Value: Understanding the Market Risk - News Heater
Evercore Inc’s Mixed Bag: Down -29.24% in 6 Months, Down -20.22% in 30 Days - investchronicle.com
GMAB’s Debt-to-Equity Ratio at 0.03: What It Means for Genmab ADR’s Future - investchronicle.com
CZR Stock Sees Decline of Approximately -4.82% in Last Five Days - knoxdaily.com
Genmab gets European approval for cervical cancer treatment - medwatch.com
Magnite Inc (MGNI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
DLocal Limited (DLO) Shares Decline Despite Market Challenges - The News Heater
Genmab ADR Inc. (GMAB) Price Performance: The Role of Supply and Demand - The InvestChronicle
Views of Wall Street’s Leading Experts on Genmab ADR - SETE News
What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News
There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News
Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register
Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Genmab stock holds Buy rating on positive trial results - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):